Details of the Drug

General Information of Drug (ID: DMCUE71)

Drug Name

PRGN-3005

Indication

Disease Entry	ICD 11	Status	REF
Refractory hematologic malignancy	2A85.5	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

CAR T Cell Therapy

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ovarian carcinoma antigen CA125 (MUC16)	TTC1PS3	MUC16_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Refractory hematologic malignancy

ICD Disease Classification

2A85.5

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Ovarian carcinoma antigen CA125 (MUC16)	DTT	MUC16	4.86E-04	5.02	2.6

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03907527) Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Precigen.